Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Supplement Articles
You have accessRestricted Access

Lipid Changes and Statins in Chronic Renal Insufficiency

Eberhard Ritz and Christoph Wanner
JASN December 2006, 17 (12 suppl 3) S226-S230; DOI: https://doi.org/10.1681/ASN.2006080919
Eberhard Ritz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Wanner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

It has been known for a long time that chronic kidney disease (CKD) is associated with dyslipidemia, but the full extent of abnormalities has been appreciated only recently, because routine laboratory tests fail to disclose the entire spectrum of lipid abnormalities. Lipids, particularly HDL cholesterol, are predictive of cardiovascular events, but a paradoxic inverse relation between cholesterol concentration and cardiovascular death has been noted in uremic patients. This currently is thought to be explained by the confounding effect of microinflammation and possibly calcification, but this is not definitely proved. Several retrospective analyses that included patients with mild or moderate CKD documented benefit from lowering of cholesterol by statins. In contrast, the Die Deutsche Diabetes Dialyse (4D) study and a small Scandinavian study failed to show a benefit from lowering of cholesterol by statins in ESRD. Pathomechanistically, it is possible that nonclassical pathomechanisms override statin-sensitive mechanisms as also suggested by the observation that statins fail to reduce carotid intima-media thickening. Although, experimentally, exposure to lipids (particularly oxidized lipids) aggravates progression, data on the effect of statins on progression in patients with CKD are not definite. The most likely explanation is that the impact of numerous confounders obscures their effect on progression. The increase in urinary protein excretion of patients who are treated with statins had been a cause of concern, but the underlying mechanism (i.e. interference with proximal tubular reabsorption of protein) meanwhile has been well documented.

Since the days of Richard Bright, it has been known that in patients with advanced renal disease, the serum is “milky,” pointing to the presence of hyperlipidemia. More recently, interest in hyperlipidemia of renal disease has been raised by the consideration that the known abnormalities in the lipid spectrum of renal patients might predispose to accelerated atherosclerosis (1). Indeed, the Seattle Group found excess death from coronary heart disease in a large proportion of the first cohort of patients who had been started on hemodialysis in Seattle (2).

Lipid Abnormalities in Renal Disease

The magnitude of lipid changes is not disclosed fully by routine laboratory chemistry, which usually shows normal total and LDL cholesterol, low HDL cholesterol, and high triglycerides. As shown in Table 1, more sophisticated analysis shows striking abnormalities: Increased VLDL; remnants and intermediate-density lipoproteins (3); prolonged persistence of postprandial chylomicron remnants (4); accumulation of small dense LDL; modification of apolipoproteins by glycation, oxidation, and carbamoylation (5); increased lipoprotein(a) [Lp(a)] (6); and accumulation of noncardioprotective acute-phase HDL (7,8). An interesting proposal was made by Shoji et al. (9), who showed that intermediate-density lipoproteins were an independent risk factor for aortic atherosclerosis. They also proposed calculation of non-HDL cholesterol (the sum of LDL and VLDL cholesterol). The latter is particularly elevated in renal failure (10).

View this table:
  • View inline
  • View popup
Table 1.

Lipid spectrum in renal diseasea

Prognostic Value of Dyslipidemia in Chronic Kidney Disease

In a prospective study, Degoulet et al. (11) made the unexpected—and at first counterintuitive—observation that in dialysis patients, low cholesterol concentrations were associated with high mortality. This key observation meanwhile was confirmed in numerous studies (12,13). In a cohort of 823 patients who were admitted for dialysis, Liu et al. (13) found in the overall cohort that an increased serum cholesterol was associated with a decreased risk for all-cause mortality, whereas in the absence of inflammation/malnutrition (22% of the cohort with serum albumin >3.6 mg/dl, C-reactive protein <10 mg/L, and IL-6 <3.09 pg/ml), an increment in baseline serum cholesterol was associated with increased mortality, as it is in the general population. This study demonstrates that the predictive value of cholesterol is confounded by concomitant inflammation.

Another controversial issue in the past had been the clinical implications of the changes in Lp(a) concentration. Lp(a) is correlated positively with higher cardiovascular risk in the general population (14) but strongly dependent of the genotype and the concomitant isoproteins of apolipoprotein(a) [apo(a)]. Individuals with low molecular weight isoforms have the highest serum Lp(a) concentrations. In renal patients, the average Lp(a) concentration is particularly increased, but the absolute serum concentration of Lp(a) is less predictive than the isoform itself. The prognosis is particularly adverse in patients with the low molecular weight apo(a) isoform compared with the high molecular weight isoform (15).

Evidence for Accelerated Atherosclerosis in Chronic Kidney Disease

Cross-sectional studies documented the high prevalence of carotid artery atherosclerosis and of atherosclerotic peripheral artery disease (16). Autopsy studies showed an excessive prevalence of advanced coronary atherosclerosis (17), and this has been confirmed by coronary angiography (18) and electron beam computed tomography (19). Coronary calcification is regarded as an index of coronary atherosclerosis. Although in renal patients calcification may not be a specific expression of coronary atherosclerosis (and partially reflect media sclerosis as well), longitudinal studies showed accelerated calcification of the coronaries compared with that in nonrenal control subjects (19,20), and this was true even in early renal disease (21).

In the first description of coronary artery disease of dialyzed patients (2), the authors postulated that in uremic patients, atherogenesis was accelerated. Indeed, several groups showed accelerated aortic atherosclerosis in the experimental model of the apoE knockout mouse with reduced renal function (22–24). This is seen even with minor reduction of renal function (e.g., uninephrectomy [22]) and responds to administration of angiotensin receptor blockers (25).

Dyslipidemia and Progression of Renal Disease

It had been known for a long time that in diverse models of renal damage, high-lipid diets or other maneuvers to induce hyperlipidemia aggravate glomerulosclerosis and progressive renal dysfunction (26–28). Oxidized lipids are particularly injurious in this context (29,30). Although various parameters of dyslipidemia predict accelerated progression in humans (31), a beneficial effect of statins on progression has not been documented beyond doubt. In several studies and meta-analyses that examined the effect of lipid lowering by statins, a trend for slower progression was seen (32), but this finding has not been consistent and significant (33). The most likely explanation is that in renal patients, the adverse effect of dyslipidemia (and the benefit from its reversal), which has been documented clearly in animal experiments, is confounded and overridden by factors that are difficult to control fully even in prospective studies (e.g., BP, proteinuria). In populations with cardiovascular disease, a recent meta-analysis showed that statin therapy seems to reduce proteinuria modestly and results in a small reduction in the rate of kidney function loss (34).

Effect of Statins on Cardiovascular Disease in Patients with Chronic Kidney Disease

In large, prospective statin trials, post hoc analysis of the proportion of the included patients who had impaired renal function (mainly stages 2 and 3 chronic kidney disease [CKD], e.g., in the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT] [35] or Cholesterol and Recurrent Events [CARE] study [36]), suggested a benefit. In the CARE study, this depended on baseline GFR and was seen primarily in the small group of patients with a GFR of <40 ml/min (37).

A similar observation had also been made in patients who received a transplant in the Assessment of Lescol in Renal Transplantation (ALERT) study. There was a tendency for fluvastatin to reduce cardiovascular death (38), including patients with reduced renal function. In a long-term open follow-up observation, the reduction of cardiovascular events became statistically significant (39).

These studies left unresolved the issue of whether statins lowered significantly cardiovascular death in patients with stages 4 and 5 CKD. This possibility was not a priori certain. Fahti et al. (40) drastically lowered LDL cholesterol by atorvastatin in patients with advanced CKD as well as in nonrenal patients with coronary artery disease. As shown in Table 2, this maneuver reduced the maximum intima-media thickness in nonrenal patients with coronary artery disease but failed to affect this index in patients with CKD.

View this table:
  • View inline
  • View popup
Table 2.

Intensive lipid-lowering effect on carotid intima-media thickness: Comparison of renal and nonrenal patients (39)a

To resolve this issue, in the prospective Die Deutsche Diabetes Dialyse (4D) study, 1255 patients who had type 2 diabetes and had been on hemodialysis for <2 yr were randomly assigned to receive placebo or 20 mg/d atorvastatin (41). In the verum group, LDL cholesterol decreased by 42% from 125 to 72 mg/dl compared with essentially no change (−1.2%) from 121 mg/dl at baseline in the placebo group during the 4-yr observation period. These values correspond to what LaRosa et al. (42) had achieved in his widely known Treating to New Targets (TNT) study, which documented impressive reduction of cardiovascular end points. Although LDL cholesterol was lowered equally effectively in the 4D study, there was a minor trend at best for an improved outcome with respect to the primary composite end point (cardiac death, fatal myocardial infarction, stroke), which failed to reach statistical significance, however. This finding is in full agreement with a recent small Scandinavian study that found significant lowering of cardiovascular end points in patients with pre–end-stage CKD but no effect whatsoever with the same dose of atorvastatin in the patients who were on hemodialysis (43).

The reasons for this unexpected failure to reduce the primary end point despite substantial lowering of LDL cholesterol are unresolved. It might be due to the operation of alternative pathomechanisms such as inflammation or calcification (44), which might override the deleterious effect of dyslipidemia. Certainly cardiovascular death in these patients was due primarily to noncoronary (or nonischemic) causes. For this reason, the power of the study in retrospect was inadequate. Another possibility to consider is that patients who would have been particularly susceptible to statin treatment may have died before reaching ESRD, because a major proportion of renal patients die from cardiovascular causes before reaching ESRD (45). In this context, it is of note (Table 3) that the major cause of death was sudden death and congestive heart failure, in good agreement with data of other studies and the US Renal Data System (www.usrds.org). Indeed, death from confirmed coronary artery disease was lowered by 19% per mmol lowering of cholesterol even in the 4D study, but patients who died from coronary heart disease composed only 9% of the patients who died. We shall have to wait for ongoing studies such as the Study of Heart and Renal Protection (SHARP) (46) and Heart and Renal Protection (HARP) Study (47,48) to be able to make evidence-based recommendations for the treatment of dyslipidemic patients who are in terminal renal failure.

View this table:
  • View inline
  • View popup
Table 3.

Causes of death in the 4D studya

What Practical Conclusions Can We Draw for Patients’ Treatment on the Basis of the Current Incomplete Knowledge?

The cardiovascular risk is excessive in patients with even minor renal dysfunction (49–51). However, at this stage of CKD, classical cardiovascular risk factors have an impact that is similar to what is seen in nonrenal patients (48). Therefore, at that stage of CKD, the same rationale applies as in the similar high-risk population of diabetes (52): in our opinion, the high cardiovascular risk justifies the use of statins as if it were secondary intervention (as in patients with a history of coronary heart disease) and not primary intervention.

The current data do not support the general use of statins in patients who are on dialysis. In the 4D study, at best, a delayed trend of a reduction of the primary cardiovascular end point was observed (albeit much less pronounced compared with patients without renal disease and statistically NS). In retrospect, the study was underpowered to evaluate specifically coronary death. In our opinion, in dialysis patients with documented coronary heart disease, the use of statins can be justified, although the benefit is not yet proved, because the adverse effect profile of the statin was not altered in renal failure; adverse effects indeed were extremely low with no cases of rhabdomyolysis and no excess frequency of creatine kinase elevation.

  • © 2006 American Society of Nephrology

References

  1. ↵
    Bagdade J, Casaretto A, Albers J: Effects of chronic uremia, hemodialysis, and renal transplantation on plasma lipids and lipoproteins in man. J Lab Clin Med 87 : 38 –48, 1976
    OpenUrlPubMed
  2. ↵
    Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290 : 697 –701, 1974
    OpenUrlCrossRefPubMed
  3. ↵
    Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P: The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant 13 : 2833 –2841, 1998
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Weintraub M, Burstein A, Rassin T, Liron M, Ringel Y, Cabili S, Blum M, Peer G, Iaina A: Severe defect in clearing postprandial chylomicron remnants in dialysis patients. Kidney Int 42 : 1247 –1252, 1992
    OpenUrlPubMed
  5. ↵
    Galle J, Wanner C: Modification of lipoproteins in uremia: Oxidation, glycation and carbamoylation. Miner Electrolyte Metab 25 : 263 –268, 1999
    OpenUrlCrossRefPubMed
  6. ↵
    Kronenberg F, Kuen E, Ritz E, Junker R, Konig P, Kraatz G, Lhotta K, Mann JF, Muller GA, Neyer U, Riegel W, Reigler P, Schwenger V, Von Eckardstein A: Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 11 : 105 –115, 2000
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, de Beer FC: Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 261 : 9644 –9651, 1986
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Hama S, Hough G, Bachini E, Grijalva VR, Wagner AC, Shaposhnik Z, Fogelman AM: The double jeopardy of HDL. Ann Med 37 : 173 –178, 2005
    OpenUrlCrossRefPubMed
  9. ↵
    Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, Inoue T, Morii H: Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 9 : 1277 –1284, 1998
    OpenUrlAbstract
  10. ↵
    Nishizawa Y, Shoji T, Kakiya R, Tsujimoto Y, Tabata T, Ishimura E, Nakatani T, Miki T, Inaba M: Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl 84 : S117 –S120, 2003
    OpenUrlCrossRefPubMed
  11. ↵
    Degoulet P, Legrain M, Reach I, Aime F, Devries C, Rojas P, Jacobs C: Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 31 : 103 –110, 1982
    OpenUrlCrossRefPubMed
  12. ↵
    Lowrie EG, Lew NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15 : 458 –482, 1990
    OpenUrlPubMed
  13. ↵
    Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 291 : 451 –459, 2004
    OpenUrlCrossRefPubMed
  14. ↵
    Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H: Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci 33 : 495 –543, 1996
    OpenUrlPubMed
  15. ↵
    Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig A, Meisl T, Konig P, Dieplinger H: The low molecular weight apo (a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: A prospective follow-up. J Am Soc Nephrol 10 : 1027 –1036, 1999
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Shoji T, Emoto M, Tabata T, Kimoto E, Shinohara K, Maekawa K, Kawagishi T, Tahara H, Ishimura E, Nishizawa Y: Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney Int 61 : 2187 –2192, 2002
    OpenUrlCrossRefPubMed
  17. ↵
    Clyne N, Lins LE, Pehrsson SK: Occurrence and significance of heart disease in uraemia. An autopsy study. Scand J Urol Nephrol 20 : 307 –311, 1986
    OpenUrlPubMed
  18. ↵
    Ikram H, Lynn KL, Bailey RR, Little PJ: Cardiovascular changes in chronic hemodialysis patients. Kidney Int 24 : 371 –376, 1983
    OpenUrlPubMed
  19. ↵
    Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27 : 394 –401, 1996
    OpenUrlCrossRefPubMed
  20. ↵
    Matsuoka M, Iseki K, Tamashiro M, Fujimoto N, Higa N, Touma T, Takishita S: Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 8 : 54 –58, 2004
    OpenUrlCrossRefPubMed
  21. ↵
    Bursztyn M, Motro M, Grossman E, Shemesh J: Accelerated coronary artery calcification in mildly reduced renal function of high-risk hypertensives: A 3-year prospective observation. J Hypertens 21 : 1953 –1959, 2003
    OpenUrlCrossRefPubMed
  22. ↵
    Buzello M, Tornig J, Faulhaber J, Ehmke H, Ritz E, Amann K: The apolipoprotein e knockout mouse: A model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 14 : 311 –316, 2003
    OpenUrlAbstract/FREE Full Text
  23. Bro S, Bentzon JF, Falk E, Andersen CB, Olgaard K, Nielsen LB: Chronic renal failure accelerates atherogenesis in apolipoprotein e-deficient mice. J Am Soc Nephrol 14 : 2466 –2474, 2003
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Massy ZA, Ivanovski O, Nguyen-Khoa T, Angulo J, Szumilak D, Mothu N, Phan O, Daudon M, Lacour B, Drueke TB, Muntzel MS: Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 16 : 109 –116, 2005
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Suganuma E, Zuo Y, Ayabe N, Ma J, Babaev VR, Linton MF, Fazio S, Ichikawa I, Fogo AB, Kon V: Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction. J Am Soc Nephrol 17 : 433 –441, 2006
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Moorhead JF, Chan MK, El-Nahas M, Varghese Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2 : 1309 –1311, 1982
    OpenUrlPubMed
  27. Wheeler DC, Nair DR, Persaud JW, Jeremy JY, Chappell ME, Varghese Z, Moorhead JF: Effects of dietary fatty acids in an animal model of focal glomerulosclerosis. Kidney Int 39 : 930 –937, 1991
    OpenUrlPubMed
  28. ↵
    Guijarro C, Kasiske BL, Kim Y, O’Donnell MP, Lee HS, Keane WF: Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis 26 : 152 –161, 1995
    OpenUrlCrossRefPubMed
  29. ↵
    Galle J, Heermeier K, Wanner C: Atherogenic lipoproteins, oxidative stress, and cell death. Kidney Int Suppl 71 : S62 –S65, 1999
    OpenUrlPubMed
  30. ↵
    Bussolati B, Deregibus MC, Fonsato V, Doublier S, Spatola T, Procida S, Di Carlo F, Camussi G: Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol 16 : 1936 –1947, 2005
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Attman PO, Alaupovic P, Samuelsson O: Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease. Kidney Int Suppl 71 : S14 –S17, 1999
    OpenUrlPubMed
  32. ↵
    Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59 : 260 –269, 2001
    OpenUrlCrossRefPubMed
  33. ↵
    Olbricht CJ, Wanner C, Thiery J, Basten A: Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group. Kidney Int Suppl 71 : S113 –S116, 1999
    OpenUrlCrossRefPubMed
  34. ↵
    Sandhu S, Wiebe N, Fried LF, Tonelli M: Statins for improving renal outcomes: A meta-analysis. J Am Soc Nephrol 17 : 2006 –2016, 2006
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 361 : 1149 –1158, 2003
    OpenUrlCrossRefPubMed
  36. ↵
    Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G: Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138 : 98 –104, 2003
    OpenUrlCrossRefPubMed
  37. ↵
    Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC: Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14 : 1605 –1613, 2003
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 361 : 2024 –2031, 2003
    OpenUrlCrossRefPubMed
  39. ↵
    Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Gronhagen-Riska C, Neumayer HH, Maes B, Ambuhl P, Hartmann A, Staffler B, Jardine AG: Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT extension study. Am J Transplant 5 : 2929 –2936, 2005
    OpenUrlCrossRefPubMed
  40. ↵
    Fathi R, Isbel N, Short L, Haluska B, Johnson D, Marwick TH: The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. Am J Kidney Dis 43 : 45 –52, 2004
    OpenUrlCrossRefPubMed
  41. ↵
    Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 : 238 –248, 2005
    OpenUrlCrossRefPubMed
  42. ↵
    LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 : 1425 –1435, 2005
    OpenUrlCrossRefPubMed
  43. ↵
    Holmberg B, Brannstrom M, Bucht B, Crougneau V, Dimeny E, Ekspong A, Granroth B, Grontoft KC, Hadimeri H, Ingman B, Isaksson B, Johansson G, Lindberger K, Lundberg L, Mikaelsson L, Olausson E, Persson B, Welin D, Wikdahl AM, Stegmayr BG: Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scand J Urol Nephrol 39 : 503 –510, 2005
    OpenUrlCrossRefPubMed
  44. ↵
    Gross M-L, Amann K, Berger I, Ritz E: Calcification of coronary intima and media: Immunohistochemistry, backscatter imaging and x-ray analysis in renal and non-renal patients [Abstract]. J Am Soc Nephrol 16 : 103A , 2005
    OpenUrlCrossRef
  45. ↵
    Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164 : 659 –663, 2004
    OpenUrlCrossRefPubMed
  46. ↵
    Baigent C, Landry M: Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 84 : S207 –210, 2003
    OpenUrlPubMed
  47. ↵
    Landray M, Baigent C, Leaper C, Adu D, Altmann P, Armitage J, Ball S, Baxter A, Blackwell L, Cairns HS, Carr S, Collins R, Kourellias K, Rogerson M, Scoble JE, Tomson CR, Warwick G, Wheeler DC: The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 47 : 385 –395, 2006
    OpenUrlCrossRefPubMed
  48. ↵
    Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B: Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. JAMA 293 : 1737 –1745, 2005
    OpenUrlCrossRefPubMed
  49. ↵
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 : 1296 –1305, 2004
    OpenUrlCrossRefPubMed
  50. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351 : 1285 –1295, 2004
    OpenUrlCrossRefPubMed
  51. ↵
    Ritz E, McClellan WM: Overview: Increased cardiovascular risk in patients with minor renal dysfunction—An emerging issue with far-reaching consequences. J Am Soc Nephrol 15 : 513 –516, 2004
    OpenUrlAbstract/FREE Full Text
  52. ↵
    Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 : 229 –234, 1998
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 17 (12 suppl 3)
Journal of the American Society of Nephrology
Vol. 17, Issue 12 suppl 3
December 2006
  • Table of Contents
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Lipid Changes and Statins in Chronic Renal Insufficiency
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Lipid Changes and Statins in Chronic Renal Insufficiency
Eberhard Ritz, Christoph Wanner
JASN Dec 2006, 17 (12 suppl 3) S226-S230; DOI: 10.1681/ASN.2006080919

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Lipid Changes and Statins in Chronic Renal Insufficiency
Eberhard Ritz, Christoph Wanner
JASN Dec 2006, 17 (12 suppl 3) S226-S230; DOI: 10.1681/ASN.2006080919
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Lipid Abnormalities in Renal Disease
    • Prognostic Value of Dyslipidemia in Chronic Kidney Disease
    • Evidence for Accelerated Atherosclerosis in Chronic Kidney Disease
    • Dyslipidemia and Progression of Renal Disease
    • Effect of Statins on Cardiovascular Disease in Patients with Chronic Kidney Disease
    • What Practical Conclusions Can We Draw for Patients’ Treatment on the Basis of the Current Incomplete Knowledge?
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Inflammatory Syndrome in Patients on Hemodialysis
  • Impact of Treatment with Calcimimetics on Hyperparathyroidism and Vascular Mineralization
  • Ischemic Heart Disease after Renal Transplantation in Patients on Cyclosporine in Spain
Show more Supplement Articles

Cited By...

  • Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease
  • Lipoprotein Abnormalities Associated with Mild Impairment of Kidney Function in the Multi-Ethnic Study of Atherosclerosis
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire